Observational studyJACC. Heart failure2026
Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.
Observational study in JACC. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundApproximately one-third of patients with heart failure with preserved ejection fraction (HFpEF) have normal pulmonary capillary wedge pressure (PCWP) at rest, with left atrial (LA) hypertension that is induced only during exercise (exercise-induced left atrial hypertension [EILAH]). EILAH may represent a discrete HFpEF phenotype or an earlier stage of HFpEF that progresses to resting left atrial hypertension (RELAH) over time.
objectivesThe authors investigated the clinical course of HFpEF patients with EILAH who underwent repeat invasive hemodynamic evaluation.
methodsThis observational study investigated the natural history of EILAH and evaluated patients who underwent multiple invasive hemodynamic studies to assess for progression from EILAH to RELAH and then identify pathophysiological correlates of progression. Consecutively evaluated patients with HFpEF and EILAH (PCWP <15 mm Hg at rest and ≥25 mm Hg during exercise) who underwent repeat invasive hemodynamic testing were identified.
resultsOf 659 patients with EILAH, 84 underwent repeat invasive hemodynamic evaluations over a median follow-up of 1.81 years (Q1-Q3: 0.48-3.40 years). Of this group, 33 (39%) patients changed to RELAH (PCWP ≥15 mm Hg at rest) and 51 (61%) did not. Patients with a change to RELAH had a greater duration between their index and repeat catheterizations (2.68 years [Q1-Q3: 1.74-3.97 years] vs 0.99 years [Q1-Q3: 0.44-2.16 years]; P = 0.001), and they experienced greater increases in N-terminal pro-B-type natriuretic peptide (interaction P = 0.036), more severe worsening in left ventricular ejection fraction (P < 0.001), right ventricular free wall longitudinal strain (P = 0.003), and more worsening tricuspid regurgitation (+15% vs +2%; P = 0.025) compared with patients who did not transition to RELAH. Of characteristics at the index evaluation, a history of atrial fibrillation (OR: 4.57 [95% CI: 1.63-12.8]), lower LA compliance (OR: 0.47 [95% CI: 0.22-0.99]), and lower pulmonary artery compliance (OR: 0.48 [95% CI: 0.25-0.93]) were independently associated with the transition to RELAH after adjusting for follow-up duration.
conclusionsMany patients with HFpEF who first present with EILAH transition to RELAH, thus suggesting that EILAH may represent an earlier stage of HFpEF. A history of atrial fibrillation, impaired LA compliance, and reduced pulmonary artery compliance are associated with progression to RELAH. These findings call for further studies of interventions enhancing atriopulmonary compliance in early-stage HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.